Amid Safety Investigation, ATTR Gene Therapy Buoyed by Good 3-Year Data

The pause in Phase III trials for a CRISPR gene therapy due to safety issues highlights the critical balance between efficacy and safety in gene therapies. Medical professionals must closely monitor adverse events and long-term outcomes to ensure patient safety while maximizing treatment benefits.